X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Study after study after study: Contract pharmacy expansion not aligned in communities 340B is meant to serve

By Nicole Longo  |    June 24, 2022
Evidence continues to show that 340B hospitals and their contract pharmacies are often not helping patients access their medicines, especially patients in socioeconomically disadvantaged areas....   Read More

New research finds gaps in charity care provided by 340B hospitals

By Nicole Longo  |    June 2, 2022
The 340B program was created to support safety-net clinics and qualifying hospitals by establishing a discounted medicine program funded by biopharmaceutical manufacturers to help vulnerable patients...   Read More

By the numbers: Contract pharmacy participation in the 340B program

By Nicole Longo  |    March 31, 2022
There are many things that set the 340B program apart from other federal prescription drug programs, namely that patients are not the primary beneficiary. While in other programs, patients qualify...   Read More

340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients

By Nicole Longo  |    February 8, 2022
The 340B program was created 30 years ago to support safety-net clinics and qualifying hospitals by establishing a discounted medicine program funded by biopharmaceutical manufacturers. The aim was...   Read More

New study finds more than half of brand medicine spending goes to the supply chain and others

By Brian Newell  |    January 7, 2022
More than half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders in 2020 according to a new analysis from the Berkeley Research Group (BRG). These new...   Read More

Making medicines more affordable: Preserving safety-net programs like 340B

By Emilie Signora  |    December 17, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s advocacy...   Read More

Fact Check: Do contract pharmacies help patients access 340B medicines? No.

By Nicole Longo  |    November 2, 2021
Over the years, there has been repeated acknowledgement that the 340B program is often not supporting the patients it was intended to help. (If you need a reminder, check out this piece in the New...   Read More

New video: Why changes to the 340B program are essential for patients

By Nicole Longo  |    October 28, 2021
The 340B program is confusing. That’s a fact that likely no one would question. In fact, it is often forgotten in broader discussions about our health care system even though it is the second largest...   Read More

New analysis adds to research questioning whether 340B is working as Congress intended

By Nicole Longo  |    October 13, 2021
As the 340B program has grown over the past decade, there has been increased interest in it and ensuring it works in the best interest of patients. Unfortunately, study after study finds that often...   Read More

340B hospitals among those that provide lowest levels of community benefit across the country

By Nicole Longo  |    July 27, 2021
The 340B program reached $38 billion in sales at the discounted price in 2020. This is a 27% increase over sales in 2019, and the program is now more than four times the size it was in 2014....   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates